Reality Check on Immune Globulin
Market access for IVIG treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: A complex market landscape across pharmacy and medical benefits, with an increase in restrictions on payer-controlled pharmacy benefit formularies
- Class Trends: How the IVIG landscape will develop in 2018, with significant M&A activity expected
- Key Findings: How developing treatments could impact market access and coverage across pharmacy and medical benefits
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.